Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

  • Kirsti AasEmail author
  • Sophie Dorothea Fosså
  • Rune Kvåle
  • Bjørn Møller
  • Tor Åge Myklebust
  • Ljiljana Vlatkovic
  • Stig Müller
  • Viktor Berge
Original Article



To study the association between time from diagnosis to radical prostatectomy (RP-interval) and prostate cancer-specific mortality (PCSM), histological findings in the RP-specimen and failure after RP (RP-failure).


Patients diagnosed with non-metastatic prostate cancer (PCa) in 2001–2010 and prostatectomized within 180 days of biopsy were identified in the Cancer Registry of Norway and the Norwegian Prostate Cancer Registry. Patients were stratified according to risk groups and RP-intervals of 0–60, 61–90, 91–120 and 121–180 days. Aalen-Johansen and Kaplan–Meier methods estimated curves for PCSM, RP-failure and overall mortality. Multivariable Cox regressions and Chi-square tests were used to evaluate the impact of RP-interval on outcomes.


In 5163 eligible patients, the median time from diagnosis to RP was 93 days (range 1–180). Risk group distribution was similar in all RP-interval groups. With almost eight years of observation, no association was found between RP-interval and PCSM in the intermediate-or high-risk groups. Increasing RP-interval did not increase the rate of adverse histological outcomes or incidence of RP-failure.


Increasing RP-interval up to 180 days was not associated with adverse oncological outcomes at eight years follow-up. These findings should be considered when planning for prostatectomy.


Mortality Outcomes Prostate cancer Radical prostatectomy Timing 



We would like to thank the Norwegian Cancer Society (Fund no. 5781243), the Radium Hospital Foundation (Project no. 335007) and the Vestre Viken Hospital Trust (Project no. 2503002) for financial support.

Author contributions

KA: Protocol/project development, Data collection or management, Data analysis, Manuscript writing/editing. SDF: Protocol/project development, Data collection or management, Data analysis, Manuscript writing/editing. RK: Data analysis, Manuscript writing/editing. BM: Protocol/project development, Data collection or management, Data analysis, Manuscript writing/editing. TÅM: Data collection or management, Data analysis, Manuscript writing/editing. LV: Data collection or management, Manuscript writing/editing. SM: Data analysis, Manuscript writing/editing. VB: Protocol/project development, Data analysis, Manuscript writing/editing.


This study was funded by the Norwegian Cancer Society (Fund no. 5781243), the Radium Hospital Foundation (Project no. 335007) and the Vestre Viken Hospital Trust (Project no. 2503002).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

345_2018_2570_MOESM1_ESM.docx (14 kb)
Supplementary file1 (DOCX 14 kb)
345_2018_2570_MOESM2_ESM.docx (17 kb)
Supplementary file2 (DOCX 17 kb)
345_2018_2570_MOESM3_ESM.docx (51 kb)
Supplementary file3 (DOCX 51 kb)
345_2018_2570_MOESM4_ESM.pdf (65 kb)
Prostate cancer-specific mortality (left) and overall mortality (right) in patients diagnosed with non-metastatic prostate cancer according to year of diagnosis (2001-07 vs 2008-10). PCa: prostate cancer (PDF 64 kb)


  1. 1.
    Cancer Registry of Norway (2017) Annual Report 2016 with Results and Improvements from the Norwegian Prostate Cancer Registry. Accessed Oct 2018
  2. 2.
    Mottet N, Bellmunt J, Bolla M et al (2017) Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. CrossRefGoogle Scholar
  3. 3.
    Neal RD, Tharmanathan P, France B et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(Suppl 1):S92–S107. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bruins HM, Aben KK, Arends TJ, Heijden AG, Witjes AJ (2016) The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: a Netherlands Cancer Registry analysis. Urol Oncol 34(4):e161–e166. CrossRefGoogle Scholar
  5. 5.
    Jensen AR, Nellemann HM, Overgaard J (2007) Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol 84(1):5–10. CrossRefPubMedGoogle Scholar
  6. 6.
    Jooste V, Dejardin O, Bouvier V et al (2016) Pancreatic cancer: wait times from presentation to treatment and survival in a population-based study. Int J Cancer. 139(5):1073–1080. CrossRefPubMedGoogle Scholar
  7. 7.
    Bourgade V, Drouin SJ, Yates DR et al (2014) Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World J Urol. 32(2):475–479. CrossRefPubMedGoogle Scholar
  8. 8.
    van den Bergh RC, Albertsen PC, Bangma CH et al (2013) Timing of curative treatment for prostate cancer: a systematic review. Eur Urol 64(2):204–215. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Redaniel MT, Martin RM, Gillatt D, Wade J, Jeffreys M (2013) Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study. BMC Cancer 13:559. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    O'Callaghan ME, Shi Z, Kopsaftis T, Moretti K (2017) Prostate cancer outcomes and delays in care. Int Urol Nephrol 49(3):449–455. CrossRefPubMedGoogle Scholar
  11. 11.
    Morini MA, Muller RL, de Castro Junior PCB, de Souza RJ, Faria EF (2018) Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter? World J Urol 36(8):1225–1231. CrossRefPubMedGoogle Scholar
  12. 12.
    Berg WT, Danzig MR, Pak JS et al (2015) Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes. Prostate 75(10):1085–1091. CrossRefPubMedGoogle Scholar
  13. 13.
    Zanaty M, Alnazari M, Ajib K et al (2018) Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. World J Urol 36(1):1–6. CrossRefPubMedGoogle Scholar
  14. 14.
    Seklehner S, Hladschik-Kermer B, Lusuardi L, Schabauer C, Riedl C, Engelhardt PF (2013) Psychological stress assessment of patients suffering from prostate cancer. Scand J Urol 47(2):101–107. CrossRefPubMedGoogle Scholar
  15. 15.
    Hernes E, Kyrdalen A, Kvale R et al (2010) Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int. 105(6):805–811. discussion 811 CrossRefPubMedGoogle Scholar
  16. 16.
    Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242. Accessed Oct 2018CrossRefGoogle Scholar
  17. 17.
    Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM (2012) Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Int 110(2):211–216. CrossRefPubMedGoogle Scholar
  18. 18.
    Pompe RS, Davis-Bondarenko H, Zaffuto E et al (2017) Population-based validation of the 2014 ISUP Gleason grade groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation or no local treatment. Prostate. CrossRefGoogle Scholar
  19. 19.
    Abdollah F, Schmitges J, Sun M et al (2012) Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 19(9):836–844. CrossRefPubMedGoogle Scholar
  20. 20.
    Stattin P, Holmberg E, Johansson JE et al (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Aas K, Axcrona K, Kvale R et al (2017) Ten-year mortality in men with nonmetastatic prostate cancer in Norway. Urology 110:140–147. CrossRefPubMedGoogle Scholar
  22. 22.
    Holmstrom B, Holmberg E, Egevad L et al (2010) Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 184(4):1322–1327. CrossRefPubMedGoogle Scholar
  23. 23.
    Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. CrossRefPubMedGoogle Scholar
  24. 24.
    Vatne K, Stensvold A, Myklebust TA et al (2017) Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncol. CrossRefPubMedGoogle Scholar
  25. 25.
    Sun M, Abdollah F, Hansen J et al (2012) Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? J Sex Med 9(11):2961–2969. CrossRefPubMedGoogle Scholar
  26. 26.
    Kvale R, Moller B, Wahlqvist R et al (2009) Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103(12):1647–1654. CrossRefPubMedGoogle Scholar
  27. 27.
    Abern MR, Aronson WJ, Terris MK et al (2013) Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate 73(4):409–417. CrossRefPubMedGoogle Scholar
  28. 28.
    Sundhedsstyrelsen (2016) Pakkeforløb for prostatakræft. Accessed Oct 2018
  29. 29.
    Norwegian Directorate of Health (2016) Pakkeforløp for prostatakreft. Accessed Oct 2018
  30. 30.
    Skyrud KD, Bray F, Moller B (2014) A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer 135(1):196–203. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kirsti Aas
    • 1
    Email author return OK on get
  • Sophie Dorothea Fosså
    • 2
    • 3
    • 4
  • Rune Kvåle
    • 2
    • 5
    • 10
  • Bjørn Møller
    • 2
  • Tor Åge Myklebust
    • 2
    • 6
  • Ljiljana Vlatkovic
    • 7
  • Stig Müller
    • 4
    • 8
  • Viktor Berge
    • 9
  1. 1.Department of SurgeryVestre Viken Hospital TrustDrammenNorway
  2. 2.Cancer Registry of NorwayOsloNorway
  3. 3.Department of OncologyOslo University HospitalOsloNorway
  4. 4.University of OsloOsloNorway
  5. 5.Department of OncologyHaukeland University HospitalBergenNorway
  6. 6.Department of Research and InnovationMøre and Romsdal Hospital TrustÅlesundNorway
  7. 7.Department of PathologyOslo University HospitalOsloNorway
  8. 8.Department of SurgeryAkershus University HospitalLørenskogNorway
  9. 9.Department of UrologyOslo University HospitalOsloNorway
  10. 10.Department of Health RegistriesNorwegian Institute of Public HealthOsloNorway

Personalised recommendations